- Treatment of CD30-positive diseases, such as Hodgkin's lymphoma, by administration of a combination of sheddase inhibitor and anti-CD30 immunotherapeutic agents
[作者:Hansen, HP; Engert, A,期刊:Expert Opinion on Therapeutic Patents, 页码:671-676 , 文章类型: Article,,卷期:2008年18-6]
CD30 is a transmembrane receptor, selectively expressed on tumor cells of certain lymphatic malignancies, such as Hodgkin's lymphoma, and therefore a privileged target for anti-CD30 antibody-based immunotherapy. Howev...
|